Jeil Pharmaceutical's Nico Chams has dominated the market for anti-smoking treatment aids with Varenicline ingredients. Analysts say that while sales of major products, including Pfizer Champix, were suspended due to the detection of impurities in NNV components in September last year, it succeeded in digging into the gap and raising its influence to the level of market monopoly.

◆ First Pharmaceutical's Nico Chams share is 1% to 87%

According to IQVIA, a pharmaceutical market research firm on the 13th, Jeil Pharmaceutical's Nico Chams' cumulative sales in the third quarter were 7.3 billion won. It increased more than nine times from 800 million won accumulated in the third quarter of